First-line Treatment of HL: Differential Treatment Strategies in Newly Diagnosed Patients with Early- versus Advanced-Stage Disease

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: April 27, 2016
Expiration Date: April 27, 2017

Expected time to complete this activity as designed: 30 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

Hodgkin lymphoma (HL) has one of the highest five-year survival rates of any hematologic malignancy, with 65%–90% of patients disease-free after five years. This high survival rate is dependent on therapeutic choices made for first-line treatment, as prognoses are improved when clinicians identify the most appropriate regimens for the individual patient early in the course of disease. In this interactive broadcast, Dr. Andrew Evens will address the critical differences in therapeutic strategies for patients who are diagnosed with early stage HL versus those who are diagnosed at an advanced stage. Through a practical review of the newest regimens and strategies, Dr. Evens will discuss the latest evidence supporting the differential use of each as first-line therapy for the newly diagnosed HL patient.

Target Audience

This activity is designed for physicians, pharmacists, physician assistants, and other health care professionals who have an interest in enhancing their clinical skills in Hodgkin lymphoma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Summarize treatment considerations for first-line therapy in patients with newly diagnosed Hodgkin lymphoma
  • Outline differences in treatment considerations for patients with limited stage versus advanced disease
  • Identify new and emerging treatments for HL that have potential to improve prognoses for patients diagnosed with early stage HL and/or for patients diagnosed with advanced disease

Agenda

First-line treatment of HL: Differential Treatment Strategies in Newly Diagnosed Patients with Early- versus Advanced-Stage Disease – Andrew M. Evens, DO, MSc, FACP

Instructions for Participation and Credit

This activity is eligible for credit through April 27, 2017. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Andrew M. Evens, DO, MSc, FACP
Professor and Chief, Division of Hematology/Oncology
Tufts University School of Medicine
Director, Tufts Cancer Center
Tufts Medical Center
Boston, Massachusetts

Dr. Evens is Professor of Medicine at Tufts University School of Medicine, as well as Chief of the Division of Hematology/Oncology and Director of the Tufts Cancer Center at Tufts Medical Center in Boston, Massachusetts. He was also named the Chan Soon-Shiong Endowed Scholar in Precision Medicine at Tufts Medical Center. Dr. Evens completed his hematology/oncology fellowship at Northwestern University Feinberg School of Medicine and The Robert H. Lurie Comprehensive Cancer Center where he was on the faculty for 15 years. Before arriving to Tufts Medical Center, he was a faculty member at the University of Massachusetts Medical School and the UMass Memorial Cancer Center where he served as the Deputy Director for the Cancer Center.

As a physician-scientist, Dr. Evens’ focus is in the biology, prognosis, and treatment of non-Hodgkin lymphoma and Hodgkin disease/lymphoma. He has designed and conducted a multitude of clinical trials in lymphoid malignancies and he has authored or co-authored more than 150 original articles in this field. Dr. Evens also maintains a R01-funded translational lymphoma laboratory examining lymphoma biology, signal transduction pathways, free radical-mediated biology, and the development of novel targeted agents for the treatment of lymphoma. Additionally, Dr. Evens is an associate editor for the British Journal of Haematology; he chairs the Hematology Panel for the VA R01 Scientific Merit Review committee; and he is a primary member of the Hodgkin Lymphoma Working Group for the NIH and NCI Steering Committee.

Accreditation

MediCom CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.50 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-16-080-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Andrew Evens has received honoraria as a consultant from Affimed, Celgene Corporation, Seattle Genetics, Inc., and Takeda Oncology. He has received grant support related to research activities from Celgene, Infinity Pharmaceuticals, Seattle Genetics, Takeda Oncology, TESARO, Inc., and 3-V Biosciences.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, and Eugene R. Tombler, PhD, FACME, Medical Director, Oncology, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

Off-Label Disclosures/Investigational Disclosures

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Dr. Evens has indicated that he does intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.

Dr. Evens has indicated that he does not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.

Hardware/Software/Internet Requirements

MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at lisa@medicaled.com

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Takeda Oncology

©2016 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Managing HL would like to recognize and thank Merck & Co., Inc., Seattle Genetics, and Takeda Oncology for their educational support of ManagingHodgkinLymphoma.com

©2017 MediCom Worldwide, Inc. All rights reserved